Meeting
2013 ASCO Annual Meeting
Phase III clinical trials with anamorelin HCl, a novel oral treatment for NSCLC cachexia.
Authors
Amy Pickar Abernethy
Duke University School of Medicine, Durham, NC
Amy Pickar Abernethy , Jennifer S. Temel , David Currow , Lyon L. Gleich , John Friend
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT01387269, NCT01387282, NCT01395914
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS9649)
DOI
10.1200/jco.2013.31.15_suppl.tps9649
Abstract #
TPS9649
Poster Bd #
41E
Abstract Disclosures
Similar Posters
Poster
2015 Palliative and Supportive Care in Oncology Symposium
Anamorelin in patients with advanced non-small cell lung cancer and cachexia: Results from the phase III studies ROMANA 1 and 2.
First Author: Jennifer S. Temel
Poster
2022 ASCO Annual Meeting
Body weight (BW) response timing to anamorelin (ANAM) in advanced non–small cell lung cancer (NSCLC)–associated cachexia.
First Author: Richard J.E. Skipworth
Poster
2016 Palliative and Supportive Care in Oncology Symposium
Efficacy of anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and low BMI (< 20 kg/m2): Post-hoc analysis of two phase III studies.
First Author: David Christopher Currow
Poster
2016 ASCO Annual Meeting
Anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and low BMI (< 20 kg/m2): A pooled efficacy data analysis of two phase 3 studies.
First Author: David Christopher Currow